巴雷特食管患者总体死亡率及病因特异性死亡率:基于人群研究的系统综述与荟萃分析
该系统综述与荟萃分析纳入7项基于人群的研究(n=34,454),评估巴雷特食管(BE)患者食管癌(EC)与非EC死亡率。BE患者全因死亡率升高(合并SMR 1.24,95%CI 1.01-1.53),部分由EC死亡风险增高驱动(SMR 8.98,95%CI 5.12-15.77);排除EC后死亡风险仍升高但有所减弱(SMR 1.21,95%CI 1-1.46)。心血管疾病死亡较高(SMR 1.16,95%CI 1.02-1.33),BE患者死于非癌病因的可能性约为EC的10倍(风险比10.71,95%CI 5.98-19.16)。
要点
- BE患者全因死亡率较一般人群升高(合并SMR 1.24,95%CI 1.01-1.53),部分由EC死亡风险驱动(SMR 8.98)。
- 排除EC后死亡风险仍升高但减弱(SMR 1.21,95%CI 1-1.46),非EC恶性肿瘤及非癌病因死亡率未见显著升高。
- BE患者死于非癌病因的可能性约为EC的10倍(风险比10.71,95%CI 5.98-19.16),心血管疾病死亡较高(SMR 1.16)。
核心结论
- BE患者全因死亡率较高,部分由EC死亡风险驱动,作者认为有必要采取个性化监测策略,在降低EC风险的同时认识到更广泛的死亡风险。
研究设计与样本
- 系统综述与荟萃分析,检索多个数据库,纳入提供标准化死亡比(SMR)的基于人群的研究,最终纳入7项研究(n=34,454)。
- SMR通过观察死亡率除以预期死亡率计算,采用随机效应模型合并SMR的对数形式。
主要发现
- 检索共获得2,826篇文章,最终纳入7项研究(n=34,454)。
- BE患者全因死亡率较一般人群升高(合并SMR 1.24,95%CI 1.01-1.53),部分由EC死亡风险增高驱动(SMR 8.98,95%CI 5.12-15.77)。
- 排除EC死亡后死亡风险仍升高但减弱(SMR 1.21,95%CI 1-1.46);非EC恶性肿瘤死亡率(SMR 1.22,95%CI 0.82-1.82)及非癌病因死亡率(SMR 1.13,95%CI 0.90-1.43)未见升高。
- 心血管疾病死亡在BE患者中较高(SMR 1.16,95%CI 1.02-1.33);BE患者死于非癌病因的可能性约为EC的10倍(风险比10.71,95%CI 5.98-19.16)。
- 排除基线时已存在EC的研究(3项)的亚组分析仍显示BE患者全因死亡率(SMR 1.12,95%CI 1.07-1.18)及EC死亡率(SMR 4.7,95%CI 3.58-6.17)升高。
临床怎么用
- 作者认为,有必要采取个性化监测策略,在降低EC风险的同时认识到BE患者更广泛的死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Current guidelines recommend endoscopic surveillance of Barrett's esophagus (BE) but do not account for competing mortality unrelated to esophageal cancer (EC). We conducted a systematic review and meta-analysis to estimate EC and non-EC mortality risk in BE patients. METHODS: We searched multiple databases for studies reporting mortality in BE. We included population-based studies providing standardized mortality ratio (SMR). The primary outcome was SMR from all causes and EC and non-EC etiologies. SMR was calculated by dividing the observed mortality over the expected mortality. Logarithmic form of SMRs was pooled using random-effects model. RESULTS: Our search yielded 2,826 articles, of which 7 studies (n = 34,454) were included. All-cause mortality was elevated in BE patients compared with population controls (pooled SMR 1.24, 95% confident interval [CI] 1.01-1.53) driven in part by increased EC mortality risk (SMR 8.98, 95 CI 5.12-15.77). The mortality risk was still increased but attenuated after excluding EC mortality (SMR 1.21, 95% CI 1-1.46). There was no increased mortality risk of non-EC malignancies (SMR 1.22, 95% CI 0.82-1.82) or mortality due to noncancer etiologies (SMR 1.13, 95% CI 0.90-1.43). Death due to cardiovascular diseases was higher in BE (SMR 1.16, 95% CI 1.02-1.33). BE patients were 10 times more likely to die from noncancer etiologies than EC (risk ratio 10.71, 95% CI 5.98-19.16). Subgroup analysis of studies that excluded prevalent EC at baseline (3 studies) also showed increased all-cause (SMR 1.12, 95% CI 1.07-1.18) and EC mortality (SMR 4.7, 95% CI 3.58-6.17) among BE patients. DISCUSSION: BE patients exhibit a higher all-cause mortality, driven in part by risk of EC mortality. A personalized approach to surveillance, mitigating risk of EC while recognizing the broader mortality risks, is warranted.
引用
- Sawas T, Jones AR, Alsawas R, et al. Overall and Cause-Specific Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-Analysis of Population-Based Studies. Am J Gastroenterol. 2025. PMID: 40162666. doi:10.14309/ajg.0000000000003456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。